Exploratory Study of the Effectiveness of Granulocyte and Monocyte Adsorptive Apheresis Before Initiation of Steroids in Patients with Active Ulcerative Colitis During the COVID-19 Outbreak (EXPECT Study): A Multicenter Prospective Clinical Trial

2020 ◽  
Author(s):  
Kazuki Kakimoto ◽  
Minoru Matsuura ◽  
Takumi Fukuchi ◽  
Hitoshi Hongo ◽  
Tsuguhiro Kimura ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Clinical Trial ◽  
Exploratory Study ◽  
Prospective Clinical Trial ◽  
Active Ulcerative Colitis ◽  
Adsorptive Apheresis

scholarly journals Exploratory Study of the Effectiveness of Granulocyte and Monocyte Adsorptive Apheresis Before Initiation of Steroids in Patients With Active Ulcerative Colitis (EXPECT Study): A Multicenter Prospective Clinical Trial

2020 ◽  
Vol 2 (4) ◽  
Author(s):  
Kazuki Kakimoto ◽  
Minoru Matsuura ◽  
Takumi Fukuchi ◽  
Hitoshi Hongo ◽  
Tsuguhiro Kimura ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Clinical Trial ◽  
Exploratory Study ◽  
Response Rate ◽  
Mucosal Healing ◽  
Prospective Clinical Trial ◽  
Aminosalicylic Acid ◽  
Open Label ◽  
Steroid Dependent ◽  
Adsorptive Apheresis

Abstract Background Granulocyte and monocyte adsorptive apheresis (GMA) has been used for therapy of steroid-dependent/refractory ulcerative colitis (UC). The aim of this study was to investigate the effectiveness of GMA in UC patients not receiving steroids. Methods We conducted a single-arm, open-label, and multicenter prospective clinical trial. UC patients who had insufficient responses to 5-aminosalicylic acid received GMA twice a week for 5 weeks. Results The response rate of all patients was 58.2% (39/67). Of the 39 patients who achieved a response, 74.4% achieved endoscopically confirmed mucosal healing. Conclusions GMA shows effectiveness in inducing remission in UC patients not receiving steroid.

Olsalazine in the Treatment of Active Ulcerative Colitis: A Placebo Controlled Clinical Trial and Assessment of Drug Disposition

1988 ◽  
Vol 23 (sup148) ◽  
pp. 61-69 ◽  
Author(s):  
D. J. Hetzel ◽  
D. J. C. Shearman ◽  
J. Labrooy ◽  
F. Bochner ◽  
D. M. Imhoff ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Clinical Trial ◽  
Drug Disposition ◽  
Controlled Clinical Trial ◽  
Active Ulcerative Colitis

Clinical trial: effects of an oral preparation of mesalazine at 4 g/day on moderately active ulcerative colitis. A phase III parallel-dosing study

2010 ◽  
Vol 46 (1) ◽  
pp. 46-56 ◽  
Author(s):  
Nobuo Hiwatashi ◽  
Yasuo Suzuki ◽  
Keiichi Mitsuyama ◽  
Akihiro Munakata ◽  
Toshifumi Hibi
Keyword(s):  
Ulcerative Colitis ◽  
Clinical Trial ◽  
Phase Iii ◽  
Active Ulcerative Colitis ◽  
Oral Preparation

scholarly journals Randomised clinical trial: once- vs. twice-daily prolonged-release mesalazine for active ulcerative colitis

2013 ◽  
Vol 37 (8) ◽  
pp. 767-775 ◽  
Author(s):  
B. Flourié ◽  
H. Hagège ◽  
G. Tucat ◽  
D. Maetz ◽  
X. Hébuterne ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Clinical Trial ◽  
Randomised Clinical Trial ◽  
Prolonged Release ◽  
Active Ulcerative Colitis

scholarly journals Remote ischemic conditioning in active ulcerative colitis: An explorative randomized clinical trial

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Line E. Godskesen ◽  
Thomas R. Lassen ◽  
Nichlas R. Jespersen ◽  
Majken Siersbæk ◽  
Yan Yan ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Clinical Trial ◽  
Randomized Clinical Trial ◽  
Active Ulcerative Colitis ◽  
Remote Ischemic Conditioning ◽  
Ischemic Conditioning
Sign in / Sign up

Export Citation Format

Share Document